ReviewJournal of blood medicine2022
Acquired Hemophilia A: Current Guidance and Experience from Clinical Practice.
Review in Journal of blood medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 45 citations in OpenAlex.
- Acquired hemophilia A following influenza vaccination: a case report and literature review.Annals of hematology · 2026Review
- Postpartum acquired hemophilia presenting as compartment syndrome: a diagnostic challenge in the emergency department.International journal of emergency medicine · 2026Article
- Atypical acquired hemophilia linked with primary biliary cholangitis: a unique case presentation.Future science OA · 2025Article
- Acquired hemophilia A: a case report and review of the literature.Journal of medical case reports · 2025Review
- A rare case of postoperative hemorrhage following laparoscopic cholecystectomy - A case report.Heliyon · 2025Article
- Post-Infectious Acquired Hemophilia A: A Case Report and Review of the Literature.Journal of Brown hospital medicine · 2025Article
- Real-World Data on Patients With Acquired Haemophilia A in Japan Undergoing Rehabilitation or With Low Activities of Daily Living Scores: The ORIHIME II Study.Haemophilia : the official journal of the World Federation of Hemophilia · 2025Observational
- Atypical Postoperative Bleeding as a First Manifestation of Acquired Hemophilia A: A Case Report.Clinical medicine insights. Case reports · 2025Article
- [Post-traumatic acquired hemophilia A: a case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Review
- Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions.American journal of hematology · 2024Review
- Bleeding Mystery Unveiled: A Case of Acquired Hemophilia A in the Shadow of Multiple Myeloma.Cureus · 2024Article
- Acquired Hemophilia A after SARS-CoV-2 Immunization: A Narrative Review of a Rare Side Effect.Vaccines · 2024Review
- A Rare Case of Life-Threatening Hemorrhage.Cureus · 2024Article
- Article
- Genetics and Epigenetics in Acquired Hemophilia A: From Bench to Bedside.Current issues in molecular biology · 2024Review
- Navigating challenges in diagnosing acquired hemophilia A: A case report from Syria.Clinical case reports · 2024Article
- Association of bullous pemphigoid with acquired hemophilia A: a case report.The Pan African medical journal · 2024Article
- Article
- Surgery and Prophylaxis with Susoctocog-Alfa in Acquired Hemophilia: Case Series and Literature Review.Journal of clinical medicine · 2023Article
- Clinicopathological Parameters of Haemophilia Patients at a Tertiary Care Centre in Northern India.Cureus · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
In acquired hemophilia A (AHA), autoantibodies to coagulation factor VIII (FVIII) neutralize FVIII activity leading to a potentially severe bleeding diathesis that carries a high rate of morbidity and mortality. This disorder is rare and occurs mainly in adults over 60 years of age or in the postpartum period. The diagnosis should be suspected in patients with new-onset bleeding without a personal or family history of bleeding and can be confirmed via specific assays for FVIII inhibitors. Treatment involves both hemostatic therapies to decrease bleeding and immune modulation strategies to re-establish immune tolerance to FVIII. There are limited data on treatment for refractory disease, based mostly on small case series. Registry studies have informed consensus guidelines for optimal hemostatic therapies and initial immunosuppressive therapies. Additional studies are needed to evaluate novel hemostatic agents and develop biomarkers to risk-stratify treatment while limiting adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.